The growth in the historic period can be attributed to frequent bleeding episodes in hemophilia b, limitations of standard half life factors, early recombinant factor ix adoption, focus on joint damage prevention, growth in hemophilia treatment centers.
The growth in the forecast period can be attributed to increasing use of long acting factors, rising access to home infusion, expanding pediatric hemophilia care, supportive reimbursement for prophylaxis, innovation in recombinant clotting factors. Major trends in the forecast period include growing adoption of extended half life factor therapies, shift toward prophylactic hemophilia management, reduced infusion frequency preferences, improved quality of life focus in hemophilia care, expansion of home based treatment models.
The increasing preference for home-based treatment is expected to propel the growth of the Idelvion market in the future. Home-based treatment refers to the administration of therapies and medications in a patient's home rather than in clinical or hospital settings, offering greater convenience and independence. The rise in home-based treatment is driven by patients seeking more control over their treatment schedules, fewer hospital visits, and improved overall quality of life. Idelvion supports home-based treatment by providing extended protection with less frequent dosing, simplified self-administration, and the flexibility needed for patients to manage hemophilia B effectively at home. For example, in June 2025, Harmony Healthcare IT, a US-based data management firm, reported that 62% of Americans had used telehealth services for their medical needs, and over three-quarters (77%) viewed telehealth as the future of healthcare. As a result, the growing preference for home-based treatment is contributing to the growth of the Idelvion market.
The growing focus on personalized medicine is expected to drive the growth of the Idelvion market moving forward. Personalized medicine tailors treatment and medical care based on an individual’s unique characteristics, preferences, and genetic profile. The rise of personalized medicine is primarily driven by advancements in genomics and data analytics, which allow for more targeted treatments. This growing demand for personalized medicine benefits Idelvion by supporting tailored treatment approaches for hemophilia B patients, optimizing dosing, and improving therapeutic outcomes. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, up from just six in 2022. As a result, the increasing focus on personalized medicine is contributing to the growth of the Idelvion market.
Healthcare infrastructure improvements are also expected to fuel the growth of the Idelvion market. Healthcare infrastructure includes the essential facilities, resources, and organizational systems needed to deliver healthcare services, such as hospitals, clinics, medical equipment, and trained personnel. Enhancing healthcare infrastructure is crucial for improving the quality of care, increasing accessibility, supporting efficient service delivery, accommodating growing populations, integrating advanced medical technologies, and effectively addressing health crises or emergencies. Healthcare infrastructure is vital for ensuring the availability and proper administration of Idelvion, a recombinant clotting factor IX used for hemophilia B treatment. For instance, in May 2023, the Department of Health and Social Care, a UK-based government agency, confirmed that the UK government would invest over $25.33 billion (£20 billion) in the New Hospital Programme, aiming to build 40 new hospitals in England by 2030. Consequently, improvements in healthcare infrastructure are driving the growth of the Idelvion market.
Major companies operating in the idelvion market are CSL Behring.
North America was the largest region in the idelvion market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idelvion market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the idelvion market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have influenced the idelvion market by increasing costs associated with recombinant protein manufacturing inputs, cold chain logistics, and specialized bioprocessing equipment. These impacts are more visible in hospital and home healthcare distribution channels across import dependent regions such as asia pacific. Higher costs can affect therapy affordability and procurement planning. At the same time, tariffs are supporting localized biologics manufacturing and strengthening regional supply resilience for hemophilia treatments.
The idelvion market research report is one of a series of new reports that provides idelvion market statistics, including idelvion industry global market size, regional shares, competitors with a idelvion market share, detailed idelvion market segments, market trends and opportunities, and any further data you may need to thrive in the idelvion industry. This idelvion market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Idelvion (albutrepenonacog alfa) is a recombinant, extended half-life factor IX replacement therapy used to treat and prevent bleeding episodes in individuals with hemophilia B. It is designed to provide long-lasting clotting factor activity, reducing the need for frequent infusions, thus offering greater convenience and improving the quality of life for patients. Idelvion helps control bleeding and prevent joint damage in individuals with hemophilia B, a genetic disorder caused by a deficiency of clotting factor IX.
The main indications for Idelvion include hemophilia B, prophylactic treatment, and on-demand treatment. Hemophilia B is a genetic disorder in which blood does not clot properly due to a lack of clotting factor IX. Idelvion is used for pediatric, adult, and geriatric patients, and it is distributed through hospitals, specialty clinics, home healthcare providers, and retail pharmacies.
The idelvion market consists of sales of prothrombin complex concentrate, immune globulin subcutaneous, and factor XIII products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The growth in the forecast period can be attributed to increasing use of long acting factors, rising access to home infusion, expanding pediatric hemophilia care, supportive reimbursement for prophylaxis, innovation in recombinant clotting factors. Major trends in the forecast period include growing adoption of extended half life factor therapies, shift toward prophylactic hemophilia management, reduced infusion frequency preferences, improved quality of life focus in hemophilia care, expansion of home based treatment models.
The increasing preference for home-based treatment is expected to propel the growth of the Idelvion market in the future. Home-based treatment refers to the administration of therapies and medications in a patient's home rather than in clinical or hospital settings, offering greater convenience and independence. The rise in home-based treatment is driven by patients seeking more control over their treatment schedules, fewer hospital visits, and improved overall quality of life. Idelvion supports home-based treatment by providing extended protection with less frequent dosing, simplified self-administration, and the flexibility needed for patients to manage hemophilia B effectively at home. For example, in June 2025, Harmony Healthcare IT, a US-based data management firm, reported that 62% of Americans had used telehealth services for their medical needs, and over three-quarters (77%) viewed telehealth as the future of healthcare. As a result, the growing preference for home-based treatment is contributing to the growth of the Idelvion market.
The growing focus on personalized medicine is expected to drive the growth of the Idelvion market moving forward. Personalized medicine tailors treatment and medical care based on an individual’s unique characteristics, preferences, and genetic profile. The rise of personalized medicine is primarily driven by advancements in genomics and data analytics, which allow for more targeted treatments. This growing demand for personalized medicine benefits Idelvion by supporting tailored treatment approaches for hemophilia B patients, optimizing dosing, and improving therapeutic outcomes. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, up from just six in 2022. As a result, the increasing focus on personalized medicine is contributing to the growth of the Idelvion market.
Healthcare infrastructure improvements are also expected to fuel the growth of the Idelvion market. Healthcare infrastructure includes the essential facilities, resources, and organizational systems needed to deliver healthcare services, such as hospitals, clinics, medical equipment, and trained personnel. Enhancing healthcare infrastructure is crucial for improving the quality of care, increasing accessibility, supporting efficient service delivery, accommodating growing populations, integrating advanced medical technologies, and effectively addressing health crises or emergencies. Healthcare infrastructure is vital for ensuring the availability and proper administration of Idelvion, a recombinant clotting factor IX used for hemophilia B treatment. For instance, in May 2023, the Department of Health and Social Care, a UK-based government agency, confirmed that the UK government would invest over $25.33 billion (£20 billion) in the New Hospital Programme, aiming to build 40 new hospitals in England by 2030. Consequently, improvements in healthcare infrastructure are driving the growth of the Idelvion market.
Major companies operating in the idelvion market are CSL Behring.
North America was the largest region in the idelvion market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idelvion market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the idelvion market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have influenced the idelvion market by increasing costs associated with recombinant protein manufacturing inputs, cold chain logistics, and specialized bioprocessing equipment. These impacts are more visible in hospital and home healthcare distribution channels across import dependent regions such as asia pacific. Higher costs can affect therapy affordability and procurement planning. At the same time, tariffs are supporting localized biologics manufacturing and strengthening regional supply resilience for hemophilia treatments.
The idelvion market research report is one of a series of new reports that provides idelvion market statistics, including idelvion industry global market size, regional shares, competitors with a idelvion market share, detailed idelvion market segments, market trends and opportunities, and any further data you may need to thrive in the idelvion industry. This idelvion market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Idelvion (albutrepenonacog alfa) is a recombinant, extended half-life factor IX replacement therapy used to treat and prevent bleeding episodes in individuals with hemophilia B. It is designed to provide long-lasting clotting factor activity, reducing the need for frequent infusions, thus offering greater convenience and improving the quality of life for patients. Idelvion helps control bleeding and prevent joint damage in individuals with hemophilia B, a genetic disorder caused by a deficiency of clotting factor IX.
The main indications for Idelvion include hemophilia B, prophylactic treatment, and on-demand treatment. Hemophilia B is a genetic disorder in which blood does not clot properly due to a lack of clotting factor IX. Idelvion is used for pediatric, adult, and geriatric patients, and it is distributed through hospitals, specialty clinics, home healthcare providers, and retail pharmacies.
The idelvion market consists of sales of prothrombin complex concentrate, immune globulin subcutaneous, and factor XIII products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Idelvion Market Characteristics
3. Idelvion Market Supply Chain Analysis
4. Global Idelvion Market Trends and Strategies
5. Idelvion Market Analysis of End Use Industries
7. Global Idelvion Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Idelvion Total Addressable Market (TAM) Analysis for the Market
9. Idelvion Market Segmentation
10. Idelvion Market Regional and Country Analysis
11. Asia-Pacific Idelvion Market
12. China Idelvion Market
13. India Idelvion Market
14. Japan Idelvion Market
15. Australia Idelvion Market
16. South Korea Idelvion Market
17. Western Europe Idelvion Market
18. UK Idelvion Market
19. Germany Idelvion Market
20. France Idelvion Market
21. Eastern Europe Idelvion Market
22. North America Idelvion Market
23. USA Idelvion Market
24. Canada Idelvion Market
25. South America Idelvion Market
26. Middle East Idelvion Market
27. Africa Idelvion Market
29. Idelvion Market Competitive Landscape and Company Profiles
32. Idelvion Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Idelvion Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses idelvion market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for idelvion? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The idelvion market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Indication: Hemophilia B; Prophylactic Treatment; On-Demand Treatment2) By Patient Age Group: Pediatrics; Adults; Geriatrics
3) By Distribution Channel: Hospitals; Specialty Clinics; Home Healthcare Providers; Retail Pharmacies
Companies Mentioned: CSL Behring
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Idelvion market report include:- CSL Behring
